Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.

This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab. The main findings show the T cell immunostimulatory...

Full description

Bibliographic Details
Main Authors: Anita K Gandhi, Tao Shi, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Josep Tabernero, Salvatore Siena, Peter H Schafer, Rajesh Chopra
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3823649?pdf=render

Internet

http://europepmc.org/articles/PMC3823649?pdf=render

Similar Items